Noteworthy clinical case studies in cancer gene therapy: Tumor-targeted Rexin-G advances as an efficacious anti-cancer agent

Abstract

Abstract. The advent of pathotropic (disease-seeking) targeting technology has ushered cancer gene therapy across the threshold of history, marking the beginning of a new epoch of medical praxis. For the first time, clinical oncologists can reach beyond the finest of catheters, beyond the reach of the most gifted surgeons, to the very fabric of metastatic disease in an effort to halt the progression and turn the tide of otherwise intractable cancers. The enabling molecular biotechnologies embodied in the leading tumor-targeted agent, Rexin-G, and its timely development as a safe and effective anti-cancer drug -from oncogene discovery and target validation, to molecular engineering of the core nanotechnologies, to the first clinical proofs-of principle, confirmatory trials, expanded access programs, and accelerated regulatory approvals -have been extensively documented in the medical literature. Therefore, this paper represents a final chapter, highlighting a series of noteworthy cases studies in the emergent field of targeted genetic medicine: case studies which, in and of themselves, reveal vital and important aspects of the molecular-genetic bio-pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and strategic medical approaches to patient care that exemplify and thereby extend the established principles of pathotropic targeting and cancer gene therapy to a new generation of clinical practitioners.

Millimeter wave radiation induces apoptosis via affecting the ratio of Bax/Bcl-2 in SW1353 human chondrosarcoma cells

“…Moreover, disrupted apoptosis contributes to drug resistance of tumor cells, which has become an efficient method in cancer treatment (23). Apoptosis is triggered by two different pathways, the intrinsic involving the mitochondria, activated by modulators within the cell itself; and the extrinsic involving death receptors, which respond mainly to extracellular stimuli (24,25).…”

Embracing the role of real life studies in the management of rare cancers

“…Understandably, this is attributed to the difficulty in recruiting enough patients to systematically study such rare manifestations. Under these circumstances, the importance of real life data that are collected via population-based studies, case series, and case reports is especially significant [2] . In the current issue of AMOR, the journal features three case reports that describe distinctly uncommon oncological scenarios.…”

Business models and opportunities for cancer vaccine developers

“…Rexin-G from Epeius (replication-incompetent, pathotropic, tumor matrix (collagen)-targeted retrovector encoding an N-terminal deletion mutant of the cyclin G1 gene) has been approved in Philippines as stand-alone therapy for the treatment of all chemotherapy-resistant solid tumors and was granted with Fast Track status, as well as Orphan Drug priorities, by the US FDA. 9 China will be the second or third largest pharmaceutical market in the world by 2020. Total vaccine market in China is estimated in $9 bn.…”